Other pathways, such as CD21 in HIV-positive patients, have also been proposed [10]. In the case of EBV-SMT, modification of immunosuppression to increase CD4 count resulted in a reduction of EBV-SMT size [10], and it was found that as CD4 levels increased in an HIV-positive male patient, tumor size shrank concurrently [10]. Here, CR2 is linked to neoplasm.